Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Apr;7(4):755-9.
doi: 10.1097/JTO.0b013e318248242c.

Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report

Arkadiusz Z Dudek  1 , Herbert Pang, Robert A Kratzke, Gregory A Otterson, Lydia Hodgson, Everett E Vokes, Hedy L Kindler; Cancer and Leukemia Group B
Affiliations
Clinical Trial

Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report

Arkadiusz Z Dudek et al. J Thorac Oncol. 2012 Apr.

Abstract

Introduction: We conducted a phase II trial of dasatinib in malignant mesothelioma (MM) patients to evaluate its toxicity and efficacy as a second-line treatment.

Methods: Patients with unresectable MM and no symptomatic effusions were given dasatinib 70 mg twice daily as part of a 28-day cycle. We also measured plasma vascular endothelial growth factor and platelet-derived growth factor b and colony stimulating factor 1 (CSF-1) and mesothelin-related protein at baseline and during therapy.

Results: Forty-six patients were enrolled in this study. Fifty percent of the first 12 patients enrolled experienced ≥grade 3 treatment-related adverse events, and therefore, the starting dose was reduced to 50 mg twice daily. Grade 3 and 4 toxicities included fatigue (11%) and pleural effusion (9%). The overall disease control rate was 32.6%, and progression-free survival at 24 weeks was 23% (95% confidence interval: 13.5-40.0%). Survival was markedly longer in patients with lower pretreatment CSF-1 levels and in patients whose CSF-1 levels decreased from baseline during therapy.

Discussion: Single-agent dasatinib has no activity in MM and is associated with pulmonary toxicities that prohibit its use in an unselected MM population.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall Survival time in relation to baseline CSF-1 level.
See this image and copyright information in PMC

References

    1. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44. - PubMed
    1. Gnoni A, Marech I, Silvestris N, et al. Dasatinib. an anti-tumour agent via Src inhibition. Curr Drug Targets. 2011 Apr;12(4):563–78. - PubMed
    1. Zucali PA, Ceresoli GL, De Vincenzo F, et al. Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev. 2011 Nov;37(7):543–58. Epub 2011 Feb 1. - PubMed
    1. Lee AW-M, States D. Both Src-dependent and Independent Mechanisms Mediate Phosphatidylinositol 3-Kinase Regulation of Colony-stimulating Factor 1-Activated Mitogen-Activated Protein Kinases in Myeloid Progenitors. Mol Cell Biol. 2000 Sep;20(18):6779–98. - PMC - PubMed
    1. Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC, O'Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, Liu G. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol. 2010 Jul 10;28(20):3316–22. - PubMed

Publication types